2023 World Conference on Lung Cancer (Posters)-EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1

EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1 - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers at The University of Texas MD Anderson Cancer Center aimed to investigate the effectiveness of docetaxel or docetaxel in combination with ramucirumab versus platinum-taxane-based regimens in patients with metastatic non-small cell lung cancer (NSCLC) who had previously progressed on platinum doublets and immune checkpoint blockade (ICB). The study also explored whether the presence of cancer gene mutations affected the response to docetaxel treatment.<br /><br />The study included male and female patients with a confirmed diagnosis of NSCLC who had progressed on platinum-based chemotherapy and anti-PD1/PDL1 ICIs, either given sequentially or in combination. The patients were divided into different treatment groups: docetaxel monotherapy, docetaxel with ramucirumab, or platinum-taxane-based regimens. Data was collected on patient demographics, clinical information at initial diagnosis, clinical information at the start of treatment, gene profiling/mutation status, and immune markers.<br /><br />The results of the study showed that the clinical benefit from docetaxel with or without ramucirumab did not depend on the presence of cancer gene mutations or PD-L1 status. However, platinum-taxane-based regimens were found to be more effective than docetaxel-based regimens in this patient population.<br /><br />Overall, this study suggests that platinum-taxane-based regimens may offer superior benefits over docetaxel-based regimens in patients with metastatic NSCLC who have previously progressed on platinum doublets and ICB. The results also highlight the need for further research into the impact of cancer gene mutations on the effectiveness of docetaxel treatment in this patient population. The study was supported by philanthropic contributions to The University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support Grant.

Asset Subtitle

Kang Qin

Meta Tag

Speaker Kang Qin

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

docetaxel

ramucirumab

platinum-taxane-based regimens

metastatic non-small cell lung cancer

NSCLC

platinum doublets

immune checkpoint blockade

cancer gene mutations

clinical benefit

PD-L1 status